Angiotech Pharmaceuticals, Inc. Reaches Agreement with Johnson & Johnson to Settle Outstanding Patent Litigation
VANCOUVER, Sept. 17 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI, TSX: ANP), announced today that it reached a favourable agreement with
Johnson & Johnson's subsidiary, Conor Medsystems ("Conor") to settle all
outstanding patent litigation with respect to Conor's CoStar(R) paclitaxel
stent.